Popular topics to explore
Metropolis Healthcare Shows Stronger Earnings Momentum
METROPOLIS is showing a meaningful improvement in its fundamental trajectory, supported by stronger revenue growth, better operating leverage and healthy profitability across its diagnostics business. The latest Q1 FY27 numbers also conti…
Metropolis Healthcare Promoters Offload ₹118 Crore Stake
METROPOLIS: On August 11, 2026, promoter entities of Metropolis Healthcare Ltd., namely Duru Shah Family Trust and Metz Advisory LLP, sold a combined 21 lakh shares (1.01% stake) at ₹564 per share, amounting to ₹118.44 crore. The transacti…
Odisha Signs 10 MoUs to Overhaul Healthcare Infrastructure and Services
To strengthen public healthcare, the Government of Odisha has signed 10 Memorandums of Understanding (MoUs) with key institutions to upgrade trauma care, medical education, diagnostics, and infrastructure. Key initiatives include partnering…
Every Growing Economy Needs Someone to Verify It.
Growth creates transactions. Transactions create the need for trust. Whether it's a medical test, a credit rating, a product certification, an ESG audit or a financial statement, verification becomes more valuable as the economy scales.…
India's Time Economy Is Getting Bigger.
Ten years ago, Indians mostly spent money on products. Today, they're increasingly spending to save time. Food delivery instead of cooking. Online investing instead of visiting a branch. Air travel instead of trains for business trips.…
METROPOLIS Underperform but Breakout.
HEG Ltd. The stock has been trading in a well-defined range for several months, with support near ₹470. A decisive breakout above ₹620–625 could open the path toward ₹690, while failure to sustain may keep the stock oscillating within the…
Technical Analysis Metropolis Healthcare Ltd.
The stock METROPOLIS is currently showing a strong bullish reversal structure. After making a major peak around 560–580 levels it went through a sharp correction phase bottoming out near the 380–400 zone. Recently the market structure has…
Metropolis Healthcare – Swing
METROPOLIS
Important Levels:
Support: 1,950 – 1,880
Resistance: 2,150 – 2,250
Structure: Consolidation after recovery
Business:
Leading diagnostics and pathology chain
Strong presence in urban healthcare…
14th May · SEBI-Registered Analyst
Currency Grow (CA & SEBI Reg IA Omkar Bhutada) · 14th May
Cipla Ltd is showing one of the cleaner cup breakout continuation structures among the charts you've shared.
CIPLA
Technical Structure
A rounded cup pattern formed after a prolonged correction and base-building phase.
Price has now decisively reclaimed the neckline zone around ₹1410–1420.
The breakout candle is wide-range and impulsive — typica…
8th May · SEBI-Registered Analyst
Currency Grow (CA & SEBI Reg IA Omkar Bhutada) · 8th May
This is a very mature multi-year base breakout setup on Metropolis Healthcare Ltd. — one of the strongest charts you’ve shared so far.
METROPOLIS
🔍 Big Picture Analysis (Monthly Chart)
1. Massive Multi-Year Consolidation
After the 2021 peak:
Stock corrected sharply
Then spent nearly 3 years building a broad base
Range approximately:
Support: 380–400
Resistance: 560–5…
When Sales Climb but Profits Tell a Different Story - Dr Lal PathLabs Q4 March 2026 Results Learning to compare quarterly results both year on year and quarter on quarter helps investors truly understand a company’s financial health and ma…
Vijaya Diagnostic Centre Limited is one of India’s leading integrated diagnostic service providers
VIJAYA
Strengths
Strong brand presence in South India, especially Telangana and Andhra Pradesh.
Integrated diagnostics model (pathology + radiology) improves operational efficiency and patient convenience.
Asset-light hub-and-spoke model…
THREE STOCKS IN WHICH DIIs INCREASED THEIR STAKE IN Q4FY26 TO KEEP ON YOUR RADAR
Domestic Institutional Investors (DIIs) have increased their stakes in several stocks during Q4FY26. Such buying activity often reflects strong confidence in a company’s fundamentals and future growth potential. Below are 3 stocks where DII…
Metropolis Healthcare Announces Landmark 3:1 Bonus Issue: First-Ever Reward for Shareholders in 2026
Leading diagnostic services provider METROPOLIS lis Healthcare Ltd. (NSE: METROPOLIS, BSE: 542650) has solidified its commitment to shareholder value with its inaugural bonus issue, announced earlier this year and now progressing toward ex…
Bonus Issue Alert: Metropolis Healthcare Goes Ex-Bonus for 3:1 Issue
Diagnostic services company METROPOLIS is set to trade ex-bonus for its 3:1 bonus share issue, meaning shareholders will receive three additional shares for every one share held. This marks the company’s first-ever bonus issue, aimed at in…
Corporate Action Alert: Bonus, Rights & Dividend — Key Dates Investors Must Track
This week’s spotlight is on major corporate actions from 5paisa Capital Ltd., Metropolis Healthcare Ltd., and DIC India Ltd.. Corporate Actions are events initiated by companies that directly impact shareholders—such as bonus issues, rights…
Metropolis Healthcare Shareholders Approve Bonus Issue
🧬 METROPOLIS shareholders have overwhelmingly approved the bonus share issuance through a postal ballot, with 98.36% votes in favor.
The e-voting process concluded on March 08, 2026, with 4,69,54,514 votes supporting the resolution, refle…
Best Pharma & Healthcare Stocks in India! 💊 With strong domestic demand, export growth, and rising healthcare spending, this sector remains structurally strong 📈 🔎 Top Pharma & Healthcare Players: * Dr. Lal PathLabs * Lupin * Kovai Me…
Metropolis Healthcare: Board Approves 3:1 Bonus Issue
Metropolis Healthcare announced a major shareholder-friendly move alongside its Q3 updates, approving a bonus issue to reward existing investors. Key Announcement: Bonus Issue Ratio: 3:1 Entitlement: Investors will receive 3 new equity s…
13th Jan · SEBI-Registered Analyst
"Invest like HNIs" by Clovek · 13th Jan
METROPOLIS
METROPOLIS launched a Centre of Genomics to scale precision diagnostics, molecular testing, and genomic research in India. The centre will support high-impact clinical areas and expand its genomic portfolio to over 500 advanced tests. It…
